General - Press Releases

Date	Title	Company
23-Oct-2023	HealthTech companies moving overseas due to manufacturing and scale-up barriers	CPI
20-Oct-2023	FarmaKeio Custom Compounding Enhances Healthcare Services Through Acquisition of State-of-the-Art Compounding Pharmacy	Newswire
19-Oct-2023	Brad Stefanovic, Clinical Operations and Innovation Leader, Joins Pro-ficiency	Newswire
18-Oct-2023	Trust.med Aims to Eliminate Counterfeit Drugs From Pharmaceutical Supply Chain With Launch of Its Contact and Verification Registry	Newswire
18-Oct-2023	Quotient Sciences Appoints Thierry Van Nieuwenhove as New CEO	Quotient Sciences
17-Oct-2023	Empaveli is the first treatment for PNH that binds to the complement protein C3.	Businesswire
17-Oct-2023	Praxis Medical Announces FDA Clearance of the EndoCore EBUS-TBNA Biopsy Device	Businesswire
17-Oct-2023	L’étude de phase IV UNITE de Teva montre qu’AJOVY® (fremanezumab) réduit les crises de migraine et les symptômes de dépression chez les personnes migraineuses souffrant d’un trouble dépressif majeur	Businesswire
17-Oct-2023	Riassunto: Lo studio UNITE di fase IV di Teva dimostra che AJOVY®(fremanezumab) ha contribuito a ridurre gli attacchi di emicrania e i sintomi depressivi nei soggetti affetti da emicrania con disturbo depressivo maggiore	Businesswire
17-Oct-2023	Samenvatting: Fase IV UNITE-studie van Teva toont aan dat AJOVY® (fremanezumab) migraineaanvallen en depressiesymptomen vermindert bij mensen die aan migraine lijden met belangrijke depressieve stoornissen	Businesswire
17-Oct-2023	Teva UNITE-Studie der Phase IV zeigt: AJOVY® (fremanezumab) reduzierte Migräne-Anfälle und depressive Symptome bei Migräne-Patienten mit schwerer depressiver Störung	Businesswire
17-Oct-2023	Resumen: El estudio UNITE de fase IV de Teva demuestra que AJOVY® (fremanezumab) redujo los ataques de migraña y los síntomas de depresión en personas con migraña y trastorno depresivo mayor	Businesswire
17-Oct-2023	First Results of Median Technologies’ iBiopsy® HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress (Oct 20-24, 2023, Madrid, Spain)	Businesswire
17-Oct-2023	Announcing Aptyx: New Brand Brings Together Market-Leading Molding, Extrusion, Coatings, and Assembly Capabilities	Businesswire
17-Oct-2023	LG Chem Announces Initiation of Two Phase 2 Trials (ROUTE & SIGNAL) of Novel Oral MC4R Agonist LB54640 in Patients with Rare Forms of Genetic Obesity	Businesswire
17-Oct-2023	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of R1 RCM Inc. (RCM) on Behalf of Investors	Businesswire
17-Oct-2023	Next Generation Drug Conjugates Market to Soar with Over 20% CAGR: Revolutionizing Rare Disease Treatment and Oncology Therapies - ResearchAndMarkets.com	Businesswire
17-Oct-2023	RNA Therapeutics Market Poised for Explosive Growth: Estimated Worth Exceeds $1.1 Billion by 2035, with a Remarkable 50% CAGR from 2026-2035 - ResearchAndMarkets.com	Businesswire
17-Oct-2023	GordonMD® Announces Investment in Radiopharmaceutical Biotech Radionetics Oncology	Businesswire
17-Oct-2023	Vetter looks ahead to further expansions to meet supply chain demand	Businesswire